checkAd

     133  0 Kommentare Genetron Health Announces Completion of Going Private Transaction - Seite 2

    The Company also announced today that it has requested that trading of its ADSs on the Nasdaq Global Market (the “Nasdaq”) be suspended as of the close of trading on March 28, 2024 (New York time). The Company has requested that Nasdaq file a Form 25 with the Securities and Exchange Commission (the “SEC”) notifying the SEC of the delisting of the ADSs on Nasdaq and the deregistration of the Company’s registered securities. The deregistration will become effective 90 days after the filing of the Form 25 or such shorter period as may be determined by the SEC. The Company intends to suspend its reporting obligations under the Securities Exchange Act of 1934, as amended, by filing a Form 15 with the SEC in approximately ten days following the filing of the Form 25. The Company’s obligations to file with the SEC certain reports and forms, including Form 20-F and Form 6-K, will be suspended immediately as of the filing date of the Form 15 and will cease once the deregistration becomes effective.

    Kroll, LLC (operating through its Duff & Phelps Opinions Practice) is serving as the financial advisor to the committee of independent and disinterested directors established by the Board (the “Special Committee”), and Davis Polk & Wardwell LLP is serving as U.S. legal counsel to the Special Committee and the Company.

    Skadden, Arps, Slate, Meagher & Flom LLP is serving as U.S. legal counsel to the investor consortium (the “Consortium”), and King & Wood Mallesons is serving as PRC legal counsel to the Consortium.

    Certain legal matters with respect to the Cayman Islands law are advised by Walkers (Hong Kong).

    About Genetron Holdings Limited

    Lesen Sie auch

    Genetron Holdings Limited (“Genetron Health” or the “Company”) (Nasdaq: GTH) is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The Company has developed a comprehensive oncology portfolio that covers the entire spectrum of cancer management, addressing needs and challenges from early screening, diagnosis and treatment recommendations, as well as continuous disease monitoring and care. Genetron Health also partners with global biopharmaceutical companies and offers customized services and products. For more information, please visit ir.genetronhealth.com.

    Seite 2 von 3




    globenewswire
    0 Follower
    Autor folgen
    Verfasst von globenewswire
    Genetron Health Announces Completion of Going Private Transaction - Seite 2 BEIJING, March 28, 2024 (GLOBE NEWSWIRE) - Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer …

    Schreibe Deinen Kommentar

    Disclaimer